Chidozie Ugwumba Sells 24,925 Shares of Clene (NASDAQ:CLNN) Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 24,925 shares of the business’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $4.81, for a total value of $119,889.25. Following the transaction, the insider owned 401,891 shares of the company’s stock, valued at $1,933,095.71. This trade represents a 5.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Wednesday, April 1st, Chidozie Ugwumba sold 4,278 shares of Clene stock. The shares were sold at an average price of $4.97, for a total value of $21,261.66.
• On Tuesday, February 3rd, Chidozie Ugwumba sold 5,559 shares of Clene stock. The shares were sold at an average price of $4.10, for a total transaction of $22,791.90.
• On Monday, February 2nd, Chidozie Ugwumba sold 3,800 shares of Clene stock. The stock was sold at an average price of $4.04, for a total transaction of $15,352.00.
• On Friday, January 30th, Chidozie Ugwumba sold 5,686 shares of Clene stock. The shares were sold at an average price of $4.13, for a total transaction of $23,483.18.
• On Thursday, January 29th, Chidozie Ugwumba sold 15,284 shares of Clene stock. The shares were sold at an average price of $4.32, for a total value of $66,026.88.
• On Wednesday, January 28th, Chidozie Ugwumba sold 8,717 shares of Clene stock. The shares were sold at an average price of $4.91, for a total value of $42,800.47.
• On Tuesday, January 27th, Chidozie Ugwumba sold 4,139 shares of Clene stock. The stock was sold at an average price of $5.08, for a total value of $21,026.12.
• On Monday, January 26th, Chidozie Ugwumba sold 6,418 shares of Clene stock. The shares were sold at an average price of $5.02, for a total value of $32,218.36.
• On Friday, January 23rd, Chidozie Ugwumba sold 5,556 shares of Clene stock. The shares were sold at an average price of $5.27, for a total value of $29,280.12.
• On Thursday, January 22nd, Chidozie Ugwumba sold 12,665 shares of Clene stock. The stock was sold at an average price of $5.32, for a total value of $67,377.80.

Clene Stock Up 12.5%

Clene stock traded up $0.64 during midday trading on Monday, hitting $5.76. The company’s stock had a trading volume of 192,488 shares, compared to its average volume of 94,606. The stock’s 50-day moving average price is $4.98 and its 200-day moving average price is $6.65. Clene Inc. has a 12 month low of $2.28 and a 12 month high of $13.50. The company has a market capitalization of $67.85 million, a PE ratio of -2.22 and a beta of 0.62.

Clene (NASDAQ:CLNN) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.14). The firm had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.03 million. As a group, equities analysts anticipate that Clene Inc. will post -5.19 EPS for the current year.

Institutional Investors Weigh In On Clene

A number of large investors have recently made changes to their positions in CLNN. Lunt Capital Management Inc. lifted its position in shares of Clene by 2.5% in the 3rd quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock valued at $315,000 after acquiring an additional 1,250 shares in the last quarter. Jones Financial Companies Lllp acquired a new stake in Clene during the 3rd quarter valued at $29,000. Geode Capital Management LLC lifted its holdings in shares of Clene by 8.0% in the fourth quarter. Geode Capital Management LLC now owns 82,079 shares of the company’s stock valued at $482,000 after purchasing an additional 6,090 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Clene in the second quarter valued at $47,000. Finally, State Street Corp boosted its position in shares of Clene by 138.4% in the fourth quarter. State Street Corp now owns 29,801 shares of the company’s stock worth $175,000 after buying an additional 17,300 shares during the period. Institutional investors and hedge funds own 23.28% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Clene in a report on Friday, January 9th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $48.00 target price on shares of Clene in a research report on Friday, March 13th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $23.00 target price on shares of Clene in a report on Thursday, March 12th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Clene has a consensus rating of “Moderate Buy” and an average target price of $32.60.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).